Amgen(AMGN)

THOUSAND OAKS, CABiotechnology3 H-1B visas (FY2023)

View 1,228 open jobs Website LinkedIn Careers Page

Focus: Amgen is a 44-year-old global biotechnology giant headquartered in California, generating $28.2B in annual revenue with a diversified portfolio across oncology, cardiovascular, bone health, immunology, and neuroscience. With 27,000 employees, Amgen operates at the scale of Big Pharma but maintains biotech innovation capabilities.

Oncology Cardiovascular Bone Health Immunology

Profile data last refreshed 56m ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

27,000

Open Jobs

1228+195 this month

Hot — 316 jobs added in 30d

Net +195 (316 new, 121 removed). Aggressive expansion phase.

2 recent layoff filings (12 mo) — 100 affected

3/26/2026 — Medford, OR · 78 affected · Layoff
3/9/2026 — 9605 Medical Center Drive, Suite 325 Rockville, MD 20850, MD · 22 affected · Layoff

Source: state DOL filings via Big Local News

Should You Work at Amgen?

AI assessment

Amgen offers stability and scale for established pharma professionals but requires comfort with patent cliff navigation and moderate pipeline concentration risk.

Why Work Here

Access to a $28.2B revenue base with stable 7% YoY growth and 17% R&D reinvestment ($4.8B in FY2025), providing resources for impactful drug development across high-burden diseases.

Data completeness

6/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

5 imminent

CORLANOR

Hiring

Stable

Revenue

$28.2B

FY2025

Key Products

PROLIA

Osteoporosis, Giant Cell Tumor of Bone, Bone Metastases

$673M Part D

LOE Approaching

Blockbuster drug generating 44% of company revenue; loss of exclusivity will materially reshape revenue profile and trigger portfolio rebalancing.

Help build intelligence for Amgen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

1,113 active job openings with strongest hiring in Commercial (246), Engineering (198), and R&D (90) suggest expansion mode and internal mobility opportunities across career stages.

Exposure to late-stage pipeline depth including Phase 3 obesity program (maridebart cafraglutide with 12 trials) and cardiovascular innovation (olpasiran for Lp(a) reduction), offering visibility to near-term catalysts.

Watch Out For

PROLIA (44% of revenue) faces imminent loss of exclusivity with no published LOE date, creating revenue cliff risk and potential restructuring pressure in coming years.
Patent cliffs totaling $182M at risk by 2030 (PENNSAID) suggest portfolio vulnerability; 20 active late-stage programs lack early-stage depth, indicating limited early-science buffer.

Generated by Claude from Amgen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

LUMAKRAS

Non-Small Cell Lung Cancer, Colorectal Cancer

$140M Part D

Peak14.4yr

First-in-class KRAS G12C inhibitor at peak stage with 15-year exclusivity runway; represents next-generation precision oncology franchise.

TEPEZZA

Thyroid Eye Disease, Graves' Orbitopathy

$129M Part D

Peak

First and only FDA-approved treatment for Graves' orbitopathy; addresses large unmet need in narrow orphan indication with pricing power.

PENNSAID

Pain, Osteoarthritis, Inflammation

$135M Part D

Peak4.3yr

Patent cliff exposure of $135M by August 2030 creates near-term revenue headwind and requires proactive pipeline augmentation.

KRYSTEXXA

Gout

$179M Part D

LOE Approaching

Second revenue contributor facing LOE; treatment for refractory gout addresses rare disease niche but lacks long-term exclusivity protection.

RAVICTI

Developmental and Epileptic Encephalopathy, STXBP1 Encephalopathy, Parkinson's Disease

$73M Part D

Peak5.8yr

Rare disease therapy with multi-indication potential; early patent cliff visibility by 2032 suggests pipeline backfill required.

CORLANOR

Heart Failure, Coronary Artery Disease, Angina Pectoris

$47M Part D

LOE Approaching1.1yr

Cardiology asset with 2027 patent cliff; first patent loss milestone signals imminent revenue erosion and competitive generic entry.

Pipeline & Clinical Trials

teprotumumab

Thyroid Eye Disease

APPROVED_FOR_MARKETING

Clinical Trials (5)

NCT05002998TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Phase 4

NCT03461211Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Phase 3

NCT06248619A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

Phase 3

+2 more

carfilzomib

Multiple Myeloma

APPROVED_FOR_MARKETING

Clinical Trials (5)

NCT03934684Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Phase 4

NCT03859427A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

AI-Detected CAC Notification and Care Facilitation

Atherosclerotic Cardiovascular Disease (ASCVD)

N/A

Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

Cancer

N/A

Clinical Trials (1)

NCT00300001Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

N/A

Observations

Anemia

N/A

Clinical Trials (1)

NCT00727571LEARN-6™: A Prospective, Observational Nursing Home Study

N/A

a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterol

Familial Hypercholesterolemia

N/A

Clinical Trials (1)

NCT03398954a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia

N/A

National Register of Actionable Mutations

Solid Tumours in Advanced Stages

N/A

Any treatment for unresectable HCC as chosen by the physician

Carcinoma, Hepatocellular

N/A

A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Tra

Hyperparathyroidism

N/A

Clinical Trials (1)

NCT01163669A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients

N/A

interferon gamma-1b

HIV Infections

N/A

Clinical Trials (2)

NCT06529731Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

NCT00002433The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During

Chemotherapy-induced Febrile Neutropenia

N/A

Clinical Trials (1)

NCT01813721Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.

N/A

Aranesp

Chronic Kidney Disease, Receiving Dialysis

N/A

Clinical Trials (5)

NCT00117039A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia

Phase 4

NCT00117065Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

Phase 4

Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthr

Psoriatic Arthritis

N/A

Clinical Trials (1)

NCT01139918Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis

N/A

MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)

Familial Hypercholesterolemia - Heterozygous

N/A

Clinical Trials (1)

NCT02517944MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)

N/A

Not applicable- observational study

Birth Defect

N/A

Clinical Trials (1)

NCT02090088Nplate® Pregnancy Exposure Registry

N/A

Pharmacological education

Fracture of Femur

N/A

Clinical Trials (1)

NCT05669040mHealth to Improve the Experience, Adherence to Drug Treatment and Positive Mental Health

N/A

ActiveHip+ mobile application

Hip Fractures

N/A

Clinical Trials (1)

NCT04859309Activating Older People After a Hip Fracture

N/A

nonmyeloablative stem cell transplant

Metastatic Solid Tumor

N/A

Clinical Trials (1)

NCT00997529Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors

N/A

Care Champion Intervention

ASCVD

N/A

Clinical Trials (1)

NCT06471036Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

N/A

OFF in experimental arm

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT00786058A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

N/A

trifluridine

Mycobacterium Avium-Intracellulare Infection

N/A

Clinical Trials (3)

NCT05198934Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Phase 3

NCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

talimogene laherparepvec

Melanoma

N/A

Clinical Trials (5)

NCT01161498Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Phase 3

NCT00769704Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Opportunistic screening for low BMD

Low Bone Density

N/A

Clinical Trials (1)

NCT05245851Clinical Deployment and Validation of Rho

N/A

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Lung Cancer

N/A

Care Transitions in Renal Disease Patients

Renal Disease

N/A

Clinical Trials (1)

NCT01842776Care Transitions in Renal Disease Patients

N/A

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients

Cystic Fibrosis

N/A

Enbrel®

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT00121056REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations

N/A

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pat

Metastatic Colorectal Cancer

N/A

Clinical Trials (1)

NCT02322736Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR

N/A

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Car

Major Cardiovascular Event

N/A

Clinical Trials (1)

NCT06295679A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

N/A

No Intervention for Observational Study

Idiopathic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT00861224Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology

N/A

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Managem

Medical Conditions to be Studied

N/A

Clinical Trials (1)

NCT02993120Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

N/A

MRI

Neuromyelitis Optica Spectrum Disorders

N/A

Clinical Trials (5)

NCT03783026A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis

Phase 4

NCT03182699Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients

Retrospective Chart Review

Idiopathic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT00454857Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

N/A

Healing Circuits™ sessions

Crohn Disease (CD)

N/A

Physician Survey

Solid Tumours

N/A

Clinical Trials (1)

NCT01998607Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw

N/A

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Stud

RAS Wild Type mCRC

N/A

Clinical Trials (1)

NCT02792478Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

N/A

standard care

Hyperparathyroidism, Secondary

N/A

Clinical Trials (3)

NCT01196715Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes

Phase 3

NCT05601492Adherence to Otezla

Phase 1

COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Pa

HIV Seropositivity

N/A

Clinical Trials (1)

NCT03139630COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients

N/A

Health Economy Register

Breast Neoplasms

N/A

Clinical Trials (1)

NCT04386629Health Economy Register

N/A

therascreen® KRAS RGQ PCR Kit

Colo-rectal Cancer

N/A

Clinical Trials (1)

NCT05347745Therascreen® KRAS RGQ PCR Kit

N/A

Otago Exercise Program

Hip Fractures

N/A

Clinical Trials (1)

NCT04748354Reducing Fall Risk Post Hip Fracture in Mild Cognitive Impairment

N/A

Diffusion Weighted Magnetic Resonance Imaging

Myeloma

N/A

Clinical Trials (1)

NCT03951220The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss

N/A

Dental implant surgery

Missing Teeth

N/A

Clinical Trials (1)

NCT04741906Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication

N/A

A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving F

Head and Neck Cancer

N/A

Corrie Lipids Digital Health Program

Cardiovascular Risk

N/A

Osteonecrosis of the Jaw (ONJ) Case Registry

Osteonecrosis of the Jaw

N/A

Clinical Trials (1)

NCT01666106Osteonecrosis of the Jaw (ONJ) Case Registry

N/A

The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvM

ASCVD

N/A

Clinical Trials (1)

NCT04197453The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

N/A

Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Post-Traumatic Headache

N/A

application

Secondary Prevention

N/A

Clinical Trials (2)

NCT03619993Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

N/A

NCT05542719Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of Atherosclerotic Cardiovascular

N/A

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Anemia

N/A

Clinical Trials (1)

NCT01444456Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

N/A

Interview Prep Quick Facts

Founded: 1980

Portfolio: 49 approved products, 161 clinical trials

Top TAs: Oncology, Immunology, Hematology

H-1B (2023): 3 approvals

Publications: 25 in PubMed

SEC Filings: 2 available

Open Roles: 1228 active jobs

Portfolio Health

Launch2 (4%)

Growth5 (10%)

Peak17 (35%)

LOE Approaching18 (37%)

Post-LOE7 (14%)

49 total products

Therapeutic Area Focus

Oncology

22 marketed550 pipeline

Immunology

13 marketed186 pipeline

Hematology

5 marketed82 pipeline

Nephrology

5 marketed82 pipeline

Financials (FY2025)

Revenue

$28.2B7%

R&D Spend

$4.8B(17%)8%

Net Income

$6.7B

Hiring Trend

Stable

1228

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2026-03-26

78 employees affected— Medford, OR

2026-03-09

22 employees affected— 9605 Medical Center Drive, Suite 325 Rockville, MD 20850, MD

Source: state DOL filings, aggregated via Big Local News

No active FDA warnings or WARN act filings; company appears operationally stable with no imminent restructuring signals, though PROLIA cliff creates medium-term uncertainty.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Treatment patterns of bone-targeted agents for the prevention of skeletal-related events in multiple myeloma in Bulgaria: a cross-sectional chart review study.

Hematology (Amsterdam, Netherlands)

2026

PMID:41709689

Treatment patterns and clinical outcomes in real-world patients with small-cell lung cancer in South Korea: A single-center experience.

mAbINJECTION · INJECTABLE

Tumor Necrosis Factor Receptor Blocking Activity

NCT04483739Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

Phase 3

NCT00117104Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis

Phase 4

NCT00002037Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

N/A

NCT02819843A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Phase 2

NCT02613416Denosumab and MRI Breast Imaging

Phase 2

NCT02273570Optimal Anemia Treatment in End Stage Renal Disease (ERSD)

N/A

3 marketed74 pipeline

Endocrinology

2 marketed51 pipeline

Cardiovascular

10 marketed34 pipeline

Neurology

5 marketed30 pipeline

International journal of cancer

2026

PMID:41826057

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Amgen(AMGN)

Should You Work at Amgen?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (30)

Key Products by Revenue

Other Products (11)

Pipeline & Clinical Trials

Open Jobs (1228)

Chef de Produit H/F Biosimilaire & Ophtalmologie, marché libéral et officinal

Brand Engagement Manager, Cardiovascular

MEDICAL MANAGER JUNIOR HEMATOLOGIE H/F

Alternance - Medical Communication Manager Junior - Oncology H/F

Sales Administrative Coordinator (Contractor)

Associate (AEM Functional Tester)

Principal Scientist – AI/ML Workflow & Ecosystem Lead (Large Molecule Discovery Informatics)

Product Manager, Rare Disease Marketing, Rare Disease Business Unit

Specialist Technical Architect

Associate Director Data Sciences

Senior Manager Biostatistics (Study Lead Statistician)

Senior Specialty Representative - Dermatology - Madison, WI

Senior Manager, Marketing

Associate Quality Control

Process Development Sr Associate

Alternance - Assistant(e) Chef(fe) de Produit Oncologie Thoracique H/F

ALTERNANCE – ASSISTANT(E) CHEF DE PRODUIT HÉMATOLOGIE – MALADIES RARES H/F

Applied AI/Automation DevOps Engineer

Process Development Associate - Pivotal Attribute Sciences

Executive Director, Clinical Development, General Medicine

Clinical Scientist Associate Director (x3)

Senior Associate

Corporate Affairs Director, Research

Senior Executive Assistant

Alternance - Chargé(e) d'Affaires Réglementaires H/F

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)

Research Publications(10)